Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 4 , Pages 273-282 , December 2008

Emerging nanopharmaceuticals

Received 2 January 2008 ,Accepted 3 June 2008.

References 

  1. Bawa R. Patents and nanomedicine. Nanomedicine. 2007;2:351–374
  2. Warheit DB, Laurence BR, Reed KL, Roach DH, Reynolds GA, Webb TR. Comparative pulmonary toxicity assessment of single-wall carbon nanotubes in rats. Toxicol Sci. 2004;77:117–125
  3. Lam CW, James JT, Latch JN, Hamilton RF, Holian A. Pulmonary toxicity of simulated lunar and Martian dusts in mice: II. Biomarkers of acute responses after intratracheal instillation. Inhal Toxicol. 2002;14:917–928
  4. National Nanotechnology Initiative . What is nanotechnology?. Available at: http://www.nano.gov/html/facts/whatIsNano.htmlAccessed 25 November 2007
  5. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318
  6. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9:E128–E147
  7. In:  Torchilin VP,  Weissing V editor. Liposomes: a practical approach. 2nd ed.. New York: Oxford University Press; 2003;
  8. Fahmy TM, Fong PM, Park J, Constable T, Saltzman WM. Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J. 2007;9:E171–E180
  9. Torchilin VP. Nanocarriers. Pharm Res. 2007;24:2333–2334
  10. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109:169–188
  11. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci. 2003;92:1343–1355
  12. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst. 2003;20:357–403
  13. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol Biosyst. 2005;1:242–250
  14. Tang N, Du G, Wang N, Liu C, Hang H, Liang W. Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst. 2007;99:1004–1015
  15. Simon JA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause. 2006;13:222–231
  16. Wiener EC, Brechbiel MW, Brothers H, Magin RL, Gansow OA, Tomalia DA, et al. Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med. 1994;31:1–8
  17. Li Y, Cheng Y, Xu T. Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. Curr Drug Discov Technol. 2007;4:246–254
  18. Kojima C, Kono K, Maruyama K, Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug Chem. 2000;11:910–917
  19. Fu HL, Cheng SX, Zhang XZ, Zhuo RX. Dendrimer/DNA complexes encapsulated in a water soluble polymer and supported on fast degrading star poly(dl-lactide) for localized gene delivery. J Control Release. 2007;124:181–188
  20. Venditto VJ, Regino CA, Brechbiel MW. PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm. 2005;2:302–311
  21. Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem. 2003;14:388–394
  22. Cheng Y, Wang J, Rao T, He X, Xu T. Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front Biosci. 2008;13:1447–1471
  23. Cheng Y, Gao Y, Rao T, Li Y, Xu T. Dendrimer-based prodrugs: design, synthesis, screening and biological evaluation. Comb Chem High Throughput Screen. 2007;10:336–349
  24. Mecke A, Uppuluri S, Sassanella TM, Lee DK, Ramamoorthy A, Baker JR, et al. Direct observation of lipid bilayer disruption by poly(amidoamine) dendrimers. Chem Phys Lipids. 2004;132:3–14
  25. Rosa Borges A, Schengrund CL. Dendrimers and antivirals: a review. Curr Drug Targets Infect Disord. 2005;5:247–254
  26. Larson DR, Zipfel WR, Williams RM, Clark SW, Bruchez MP, Wise FW, et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science. 2003;300:1434–1436
  27. Kaji N, Tokeshi M, Baba Y. Quantum dots for single bio-molecule imaging. Anal Sci. 2007;23:21–24
  28. Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem. 2007;18:1391–1396
  29. Muller-Borer BJ, Collins MC, Gunst PR, Cascio WE, Kypson AP. Quantum dot labeling of mesenchymal stem cells. J Nanobiotechnol. 2007;5:9
  30. Alivisatos AP, Gu W, Larabell C. Quantum dots as cellular probes. Annu Rev Biomed Eng. 2005;7:55–76
  31. Hoshino A, Fujioka K, Oku T, Nakamura S, Suga M, Yamaguchi Y, et al. Quantum dots targeted to the assigned organelle in living cells. Microbiol Immunol. 2004;48:985–994
  32. Howarth M, Takao K, Hayashi Y, Ting AY. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc Natl Acad Sci U S A. 2005;102:7583–7588
  33. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007;7:3065–3070
  34. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed. 2007;18:241–268
  35. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969–976
  36. Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 2004;4:11–18
  37. Cho SJ, Maysinger D, Jain M, Roder B, Hackbarth S, Winnik FM. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir. 2007;23:1974–1980
  38. Green M, Howman E. Semiconductor quantum dots and free radical induced DNA nicking. Chem Commun (Camb). 2005;121–123
  39. Choi AO, Cho SJ, Desbarats J, Lovric J, Maysinger D. Quantum dot–induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnol. 2007;5:1
  40. Lovric J, Cho SJ, Winnik FM, Maysinger D. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol. 2005;12:1227–1234
  41. Zhu MQ, Han JJ, Li AD. CdSe/CdS/SiO2 core/shell/shell nanoparticles. J Nanosci Nanotechnol. 2007;7:2343–2348
  42. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis. 2007;13:746–757
  43. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263:797–800
  44. Till MC, Simkin MM, Maebius S. Nanotech meets the FDA: a success story about the first nanoparticulate drugs approved by the FDA. Nanotechnol Law Business. 2005;2:163–167
  45. Damascelli B, Cantu G, Mattavelli F, Tamplenizza P, Bidoli P, Leo E, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer. 2001;92:2592–2602
  46. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res. 2005;11:4136–4143
  47. Kattan J, Droz JP, Couvreur P, Marino JP, Boutan-Laroze A, Rougier P, et al. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs. 1992;10:191–199
  48. Schwarz C, Mehnert W, Lucks JS, Muller RH. Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization, and sterilization. J Control Release. 1994;30:83–96
  49. Muller RH, Schwarz C, Mehnert W, Lucks JS. Production of solid lipid nanoparticles (SLN) for controlled drug delivery. Proc Int Symp Control Rel Bioact Mater. 1993;20:480–481
  50. Liedtke S, Wissing S, Muller RH, Mader K. Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int J Pharm. 2000;196:183–185
  51. Gasco MR, inventor. Method for producing solid lipid microspheres having a narrow size distribution. United States patent US 5250236. 1993 Oct 5.
  52. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm. 1996;43:110–115
  53. Gasco MR. Solid lipid nanospheres from warm microemulsions. Pharm Technol Eur. 1997:9, 52-4, 6-8.
  54. Cavalli R, Caputo O, Marengo E, Pattarino F, Gasco MR. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie. 1998;53:392–396
  55. Igartua M, Saulnier P, Heurtault B, Pech B, Proust JE, Pedraz JL, et al. Development and characterization of solid lipid nanoparticles loaded with magnetite. Int J Pharm. 2002;233:149–157
  56. Sjostrom B, Kaplun A, Talmon Y, Cabane B. Structures of nanoparticles prepared from oil-in-water emulsions. Pharm Res. 1995;12:39–48
  57. Shahgaldian P, Da Silva E, Coleman AW, Rather B, Zaworotko MJ. Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm. 2003;253:23–38
  58. Dubes A, Parrot-Lopez H, Abdelwahed W, Degobert G, Fessi H, Shahgaldian P, et al. Scanning electron microscopy and atomic force microscopy imaging of solid lipid nanoparticles derived from amphiphilic cyclodextrins. Eur J Pharm Biopharm. 2003;55:279–282
  59. Eldem T, Speiser P, Hincal A. Optimization of spray-dried and -congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res. 1991;8:47–54
  60. Speiser P, inventor; Dr. Rentschler Arzneimittel GmbH & Co, assignee. Lipid nano-pellets as excipient system for perorally administered drugs. United States patent US 4880634. 1989 Nov 14.
  61. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res. 2000;42:337–343
  62. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target. 2002;10:327–335
  63. Bargoni A, Cavalli R, Zara GP, Fundaro A, Caputo O, Gasco MR. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II—tissue distribution. Pharmacol Res. 2001;43:497–502
  64. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005;107:215–228
  65. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999;59:299–307
  66. Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb). 2005;85:415–420
  67. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev. 2005;57:2063–2079
  68. Smart JD. Buccal drug delivery. Expert Opin Drug Deliv. 2005;2:507–517
  69. Mackay M, Phillips J, Hastewell J. Peptide drug delivery: colonic and rectal absorption. Adv Drug Deliv Rev. 1997;28:253–273
  70. Yamaguchi Y, Nakamura N, Nagasawa T, Kitagawa A, Matsumoto K, Soma Y, et al. Enhanced skin regeneration by nanoegg formulation of all-trans retinoic acid. Pharmazie. 2006;61:117–121
  71. Kalariya M, Padhi BK, Chougule M, Misra A. Clobetasol propionate solid lipid nanoparticles cream for effective treatment of eczema: formulation and clinical implications. Indian J Exp Biol. 2005;43:233–240
  72. Wissing SA, Muller RH. Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm. 2003;254:65–68
  73. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328:191–195
  74. Ganem-Quintanar A, Silva-Alvarez M, Alvarez-Roman R, Casas-Alancaster N, Cazares-Delgadillo J, Quintanar-Guerrero D. Design and evaluation of a self-adhesive naproxen-loaded film prepared from a nanoparticle dispersion. J Nanosci Nanotechnol. 2006;6:3235–3241
  75. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392
  76. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;1:241–263
  77. Guo X, Szoka FC. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc Chem Res. 2003;36:335–341
  78. Shvedova AA, Castranova V, Kisin ER, Schwegler-Berry D, Murray AR, Gandelsman VZ, et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A. 2003;66:1909–1926
  79. Shvedova AA, Kisin E, Murray AR, Schwegler-Berry D, Gandelsman VZ, Baron P, et al. Exposure of human bronchial cells to carbon nanotubes caused oxidative stress and cytotoxicity. In: Proceedings of the Meeting of the Society for Free Radical Research (SFRR) Europe 2003, June 26-29; Ioannina, Greece. Philadelphia: Taylor & Francis Group; 2004;p. 91–103
  80. Lam CW, James JT, McCluskey R, Hunter RL. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci. 2004;77:126–134
  81. Lam PK, Chan ES, Ho WS, Liew CT. In vitro cytotoxicity testing of a nanocrystalline silver dressing (Acticoat) on cultured keratinocytes. Br J Biomed Sci. 2004;61:125–127
  82. Poon VK, Burd A. In vitro cytotoxity of silver: implication for clinical wound care. Burns. 2004;30:140–147
  83. Soto K, Carrasco A, Powell TG, Garza KM, Murr LE. Comparative in vitro cytotoxicity assessment of some manufactured nanoparticulate materials characterized by transmission electron microscopy. J Nanoparticle Res. 2005;7:145–169
  84. Shirai Y, Osgood AJ, Zhao Y, Yao Y, Saudan L, Yang H, et al. Surface-rolling molecules. J Am Chem Soc. 2006;128:4854–4864
  85. Mousa SA, Bharali DJ, Armstrong D. From nutraceuticals to pharmaceuticals to nanopharmaceuticals: a case study in angiogenesis modulation during oxidative stress. Mol Biotechnol. 2007;37:72–80
  86. Lesinski GB, Sharma S, Varker KA, Sinha P, Ferrari M, Carson WE. Release of biologically functional interferon-alpha from a nanochannel delivery system. Biomed Microdevices. 2005;7:71–79
  87. Anderson DG, Burdick JA, Langer R. Materials science. Smart biomaterials. Science. 2004;305:1923–1924
  88. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003;21:1184–1191
  89. Maynard AD. Nanotechnology: a research strategy for addressing risks. Woodrow Wilson International Center for Scholars: Project on emerging nanotechnologies. 2006. Available from: http://www.nanotechproject.org/file_download/files/PEN3_Risk.pdf.

 No conflict of interest was reported by the authors of this article.

PII: S1549-9634(08)00084-1

doi: 10.1016/j.nano.2008.06.002

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 4, Issue 4 , Pages 273-282 , December 2008

Article Tools

* Image Usage & Resolution